[Evidence for thrombosis prophylaxis to high-risk patients].
Själander
Anders
A
Anders.Sjalander@LVN.se
Jansson
Jan-Håkan
JH
Bergqvist
David
D
Eriksson
Henry
H
Svensson
Peter
P
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight